Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.244
https://www.valueinhealthjournal.com/article/S1098-3015(15)02320-7/fulltext
Section Title :
Research Podium Presentations - Session 1
Section Order :
2468
First Page :
A818
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02320-7&doi=10.1016/j.jval.2015.09.244